PMID- 30114639
OWN - NLM
STAT- MEDLINE
DCOM- 20190115
LR  - 20220321
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 107
DP  - 2018 Nov
TI  - Honokiol: An anticancer lignan.
PG  - 555-562
LID - S0753-3322(18)32782-3 [pii]
LID - 10.1016/j.biopha.2018.08.054 [doi]
AB  - BACKGROUND: Honokiol ((3',5-di-(2-propenyl)-1,1'-biphenyl-2,2'-diol), a lignan, 
      is a promising antitumor compound, having exerted activity against a number of 
      human cancer cell lines. Honokiol has inhibitory role on the proliferation, 
      invasion and survival of cancer cells in in vitro as well as in vivo studies. It 
      interferes with signaling pathways components in order to elicit the anticancer 
      effect. SCOPE AND APPROACH: In present review, the published data on the efficacy 
      of honokiol against various cancer cell lines and tumor-bearing animal models has 
      been presented and discussed. KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the 
      expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein 
      expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), 
      Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 
      methyltransferase among numerous other anticancer functions. It increases bone 
      morphogenetic protein 7 (BMP7), Bax protein, among others. It does so by 
      interfering with the major checkpoints such as nuclear factor kappa B (NF-kappaB), 
      and activator of transcription 3 (STAT3), mammalian target of rapamycin (m-TOR), 
      epidermal growth factor receptor (EGFR), Sonic hedgehog (SHH). It promotes the 
      efficacy of several anticancer drugs and radiation tolerance. The derivatization 
      of honokiol results in compounds with interesting attributes in terms of cancer 
      control. This review will shed light on the scopes and hurdles in the relevance 
      of the bioactive lignan honokiol in cancer management.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Rauf, Abdur
AU  - Rauf A
AD  - Department of Chemistry, University of Swabi, Anbar-23561, Khyber Pakhtunkhwa, 
      Pakistan. Electronic address: abdurrauf@uoswabi.edu.pk.
FAU - Patel, Seema
AU  - Patel S
AD  - Bioinformatics and Medical Informatics Research Center, San Diego State 
      University, San Diego 92182, California, USA.
FAU - Imran, Muhammad
AU  - Imran M
AD  - University Institute of Diet & Nutritional Sciences, Faculty of Allied and Health 
      Sciences, The University of Lahore-Pakistan.
FAU - Maalik, Aneela
AU  - Maalik A
AD  - Department of Chemistry, COMSATS University Abbottabad Campus, 22060-Abbottabad, 
      Pakistan.
FAU - Arshad, Muhammad Umair
AU  - Arshad MU
AD  - Faculty of Home and Food Sciences, Government College University, Faisalabad, 
      Pakistan.
FAU - Saeed, Farhan
AU  - Saeed F
AD  - Faculty of Home and Food Sciences, Government College University, Faisalabad, 
      Pakistan.
FAU - Mabkhot, Yahia N
AU  - Mabkhot YN
AD  - Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, 
      Riyadh 1451, Kingdom of Saudi Arabia.
FAU - Al-Showiman, Salim S
AU  - Al-Showiman SS
AD  - Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, 
      Riyadh 1451, Kingdom of Saudi Arabia.
FAU - Ahmad, Nazir
AU  - Ahmad N
AD  - Faculty of Home and Food Sciences, Government College University, Faisalabad, 
      Pakistan.
FAU - Elsharkawy, Eman
AU  - Elsharkawy E
AD  - Department of Chemistry, Faculty of Science, Northern Borders University, Saudi 
      Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180813
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Lignans)
RN  - 11513CCO0N (honokiol)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Biphenyl Compounds/*pharmacology
MH  - Humans
MH  - Lignans/*pharmacology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Breast cancer
OT  - Honokiol
OT  - Ovarian and lung cancer
OT  - Prostate cancer
OT  - Signaling pathways
EDAT- 2018/08/17 06:00
MHDA- 2019/01/16 06:00
CRDT- 2018/08/17 06:00
PHST- 2018/04/25 00:00 [received]
PHST- 2018/07/20 00:00 [revised]
PHST- 2018/08/10 00:00 [accepted]
PHST- 2018/08/17 06:00 [pubmed]
PHST- 2019/01/16 06:00 [medline]
PHST- 2018/08/17 06:00 [entrez]
AID - S0753-3322(18)32782-3 [pii]
AID - 10.1016/j.biopha.2018.08.054 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Nov;107:555-562. doi: 10.1016/j.biopha.2018.08.054. 
      Epub 2018 Aug 13.